Thanks. We tried to address the issue of how many shares R&R actually had, and I don't think it was anywhere near the potential 2.5M that is often quoted. There is actually no proof that they received shares from any of those warrants. I think they are out and have been for a long time.
The UMK-121 clinical trials appear to still be in the recruitment stage. I'm not sure about the timing of Iceman's calls ($50 in May), but successful trials should put the share price in that vicinity.